Showing 1 - 4 results of 4 for search 'Allan R. Tenorio', query time: 0.03s Refine Results
  1. 1
    Growth analysis among adolescents with moderate-to-severe atopic dermatitis receiving upadacitinib in combination with topical corticosteroids in Japan: A case study series from a phase 3, randomized, controlled trial (Rising Up)

    Growth analysis among adolescents with moderate-to-severe atopic dermatitis receiving upadacitinib in combination with topical corticosteroids in Japan: A case study series from a... by Toshiaki Tanaka, MD, Takuya Sasaki, BA, Kimitoshi Ikeda, PhD, Jianzhong Liu, MD, Allan R. Tenorio, MD, Yukihiro Ohya, PhD

    Published 2022-09-01
    Get full text
    Article
  2. 2
    Long-term safety and impact of immune recovery in heavily treatment-experienced adults receiving fostemsavir for up to 5 years in the phase 3 BRIGHTE study

    Long-term safety and impact of immune recovery in heavily treatment-experienced adults receiving fostemsavir for up to 5 years in the phase 3 BRIGHTE study by Josep M. Llibre, Judith A. Aberg, Sharon Walmsley, Juan Velez, Carlos Zala, Brenda Crabtree Ramírez, Bronagh Shepherd, Rimi Shah, Andrew Clark, Allan R. Tenorio, Amy Pierce, Fangfang Du, Bo Li, Marcia Wang, Shiven Chabria, Michael Warwick-Sanders

    Published 2024-05-01
    Get full text
    Article
  3. 3
    Week 240 Efficacy and Safety of Fostemsavir Plus Optimized Background Therapy in Heavily Treatment-Experienced Adults with HIV-1

    Week 240 Efficacy and Safety of Fostemsavir Plus Optimized Background Therapy in Heavily Treatment-Experienced Adults with HIV-1 by Judith A. Aberg, Bronagh Shepherd, Marcia Wang, Jose V. Madruga, Fernando Mendo Urbina, Christine Katlama, Shannon Schrader, Joseph J. Eron, Princy N. Kumar, Eduardo Sprinz, Margaret Gartland, Shiven Chabria, Andrew Clark, Amy Pierce, Max Lataillade, Allan R. Tenorio

    Published 2023-09-01
    Get full text
    Article
  4. 4
    Changes over time in creatinine clearance and comparison of emergent adverse events for HIV-positive adults receiving standard doses (300 mg/day) of lamivudine-containing antiretroviral therapy with baseline creatinine clearance of 30-49 vs ≥50 mL/min.

    Changes over time in creatinine clearance and comparison of emergent adverse events for HIV-positive adults receiving standard doses (300 mg/day) of lamivudine-containing antiretro... by Lisa L Ross, A Sarah Walker, Yu Lou, Allan R Tenorio, Diana M Gibb, Julia Double, Charles Gilks, Cynthia C McCoig, Paula Munderi, Godfrey Musoro, Cissy M Kityo, Heiner Grosskurth, James Hakim, Peter N Mugyenyi, Amy Cutrell, Teodora Perger, Mark S Shaefer

    Published 2019-01-01
    Get full text
    Article

Search Tools: